SOUTH SAN FRANCISCO, Calif., Feb. 27, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced a reorganization of its Clinical and Scientific Advisory Board (CSAB). The CSAB will provide counsel on clinical and scientific development of the company’s portfolio of oncology therapeutic and supportive care products.
